Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I—initial work-up and medical management
Purpose: Benign prostatic hyperplasia (BPH) is a histologic diagnosis describing
proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The …
proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The …
Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms
Context Lower urinary tract symptoms (LUTS) are common, often bothersome, and have
multifactorial aetiology. Objective To present a summary of the 2023 version of the European …
multifactorial aetiology. Objective To present a summary of the 2023 version of the European …
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction
M Oelke, A Bachmann, A Descazeaud, M Emberton… - European urology, 2013 - Elsevier
OBJECTIVE: To present a summary of the 2013 version of the European Association of
Urology guidelines on the treatment and follow-up of male lower urinary tract symptoms …
Urology guidelines on the treatment and follow-up of male lower urinary tract symptoms …
Benign prostatic hyperplasia and lower urinary tract symptoms
AV Sarma, JT Wei - New England Journal of Medicine, 2012 - Mass Medical Soc
Key Clinical Points Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms Lower
urinary tract symptoms—including obstructive symptoms (eg, urinary hesitancy and weak …
urinary tract symptoms—including obstructive symptoms (eg, urinary hesitancy and weak …
Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders
MC Michel, L Cardozo, CJ Chermansky, F Cruz… - Pharmacological …, 2023 - ASPET
Overactive bladder syndrome with and without urinary incontinence and related conditions,
signs, and disorders such as detrusor overactivity, neurogenic lower urinary tract …
signs, and disorders such as detrusor overactivity, neurogenic lower urinary tract …
Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder
BACKGROUND: Lower urinary tract symptoms (LUTS) are prevalent among men.
OBJECTIVE: To describe the prevalence, severity, and symptom bother of LUTS in all men …
OBJECTIVE: To describe the prevalence, severity, and symptom bother of LUTS in all men …
Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence
KE Andersson, CR Chapple, L Cardozo… - Current opinion in …, 2009 - journals.lww.com
Pharmacological treatment of overactive bladder: report from... : Current Opinion in Urology
Pharmacological treatment of overactive bladder: report from the International Consultation on …
Pharmacological treatment of overactive bladder: report from the International Consultation on …
Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double‐blind, placebo‐, and active‐controlled thorough QT study
M Malik, EM Van Gelderen, JH Lee… - Clinical …, 2012 - Wiley Online Library
Potential effects of the selective β3‐adrenoceptor agonist mirabegron on cardiac
repolarization were studied in healthy subjects. The four‐arm, parallel, two‐way crossover …
repolarization were studied in healthy subjects. The four‐arm, parallel, two‐way crossover …
[HTML][HTML] Management of urinary incontinence
GA DeMaagd, TC Davenport - Pharmacy and Therapeutics, 2012 - ncbi.nlm.nih.gov
Accepted for publication January 23, 2012. cerebrovascular disease, diabetes,
hypertension, obstructive sleep apnea, and normal-pressure hydrocephalus. Functional …
hypertension, obstructive sleep apnea, and normal-pressure hydrocephalus. Functional …
Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency
SA Kaplan, K McCammon, R Fincher… - The Journal of …, 2013 - auajournals.org
Purpose: VICTOR was a 12-week, double-blind, placebo controlled trial assessing the safety
and tolerability of solifenacin plus tamsulosin in men with residual overactive bladder …
and tolerability of solifenacin plus tamsulosin in men with residual overactive bladder …